Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance

被引：0
|
作者：
Sharareh Seifi
Babak Salimi
Zahra Esfahani Monfared
Cyrus Sabahi
Hamidreza Kafi
Adnan Khosravi
机构：
[1] National Research Institute of Tuberculosis and Lung Diseases (NRITLD),Chronic Respiratory Disease Research Center
[2] Shahid Beheshti University of Medical Sciences,Faculty of Pharmacy
[3] Tehran University of Medical Sciences,Medical Department
[4] Orchid Pharmed Company,undefined
[5] Masih Daneshvari Hospital,undefined
来源：
Journal of Pharmaceutical Policy and Practice | / 16卷
关键词：
Non-small cell lung cancer; Observational study; Pemetrexed; Post-marketing surveillance; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
    Seifi, Sharareh
    Salimi, Babak
    Monfared, Zahra Esfahani
    Sabahi, Cyrus
    Kafi, Hamidreza
    Khosravi, Adnan
    JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE, 2023, 16 (01)
  • [2] SAFETY AND EFFECTIVENESS OF PEMETREXED IN PATIENTS WITH NON-SMALL CELL LUNG CANCER IN JAPAN BASED ON POST-MARKETING SURVEILLANCE
    Okubo, Sumiko
    Kobayashi, Noriko
    Taketsuna, Masanori
    Enatsu, Sotaro
    Nishiuma, Shinichi
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S485 - S485
  • [3] Pemetrexed-related interstitial lung disease reported from post marketing surveillance (malignant pleural mesothelioma/non-small cell lung cancer)
    Tomii, Keisuke
    Kato, Terufumi
    Takahashi, Masashi
    Noma, Satoshi
    Kobashi, Yoichiro
    Enatsu, Sotaro
    Okubo, Sumiko
    Kobayashi, Noriko
    Kudoh, Shoji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (04) : 350 - 356
  • [4] Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
    Fujimoto, Nobukazu
    Akamatsu, Ayumi
    Honda, Chikara
    Aoki, Miki
    Ohe, Yuichiro
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, : 1321 - 1328
  • [5] Pemetrexed in the treatment of non-small-cell lung cancer and malignant pleural mesothelioma
    Kowalski, Dariusz M.
    Krawczyk, Pawel
    Jaskiewicz, Piotr
    Badurak, Pawel
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2011, 7 (06): : 292 - 300
  • [6] Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance
    Yamamoto, Nobuyuki
    Kamitani, Tetsu
    Kanda, Kingo
    Ito, Yuichiro
    Hamada, Masahiro
    Ozaki, Masahiko
    Takeuchi, Noriko
    Yamada, Tomoko
    Kawano, Masaki
    Maekawa, Shinichiroh
    Kato, Terufumi
    CANCER SCIENCE, 2022, 113 (09) : 3110 - 3119
  • [7] NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer
    Leal, Jose Luis
    Peters, Geoffrey
    Szaumkessel, Marcin
    Leong, Trishe
    Asadi, Khashayar
    Rivalland, Gareth
    Do, Hongdo
    Senko, Clare
    Mitchell, Paul L.
    Quing, Chai Zi
    Dobrovic, Alexander
    Thapa, Bibhusal
    John, Thomas
    LUNG CANCER, 2020, 146 : 154 - 159
  • [8] The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study
    Ohe, Yuichiro
    Yamazaki, Naoya
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    Yoh, Kiyotaka
    Kitano, Shigehisa
    Hashimoto, Hideyuki
    Murayama, Ayako
    Nakane, Sayuri
    Gemma, Akihiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (06) : 623 - 632
  • [9] Role of pemetrexed in non-small cell lung cancer
    Longo-Sorbello, Giuseppe S. A.
    Chen, Bobin
    Budak-Alpdogan, Tulin
    Bertino, Joseph R.
    CANCER INVESTIGATION, 2007, 25 (01) : 59 - 66
  • [10] Pemetrexed in advanced non-small cell lung cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    Bareschino, Maria Anna
    Schettino, Clorinda
    Sacco, Paola Claudia
    Zeppa, Rosario
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (02) : 311 - 317
12345